Role of endothelin in the pathogenesis of hypertension

Mayo Clinic Proceedings

Volumn 80, Issue 1, 2005, Pages 84-96

  Perez Del Villar, Candelas ^a   Garcia Alonso, Carlos Javier ^a   Feldstein, Carlos A ^b   Juncos, Luis A ^a   Romero, J Carlos ^a  

^a Mayo Clinic   (United States)

^b HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; DEOXYCORTICOSTERONE ACETATE; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; SARAFOTOXIN;

CARDIOVASCULAR EFFECT; CLEARANCE; FIBROSIS; HEART; HEMODYNAMICS; HIGH SODIUM INTAKE; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY TUBULE FUNCTION; KIDNEY VEIN; MOLECULAR RECOGNITION; NATRIURESIS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; SODIUM BALANCE; SODIUM LOAD; TISSUE INJURY; VASOCONSTRICTION; VASODILATATION;

EID: 11344276246     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/80.1.84     Document Type: Review

References (112)

1. Hickey KA, Rubanyi G, Paul RJ, Highsmith RF. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol. 1985;248(5, pt 1):C550-C556.
2. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
3. Kloog Y, Ambar I, Sokolovsky M, Kochva E, Wollberg Z, Bdolah A. Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain. Science. 1988;242:268-270.
4. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family, three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 1989;86:2863-2867.
5. Xu D, Emoto N, Giaid A, et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 1994;78:473-485.
6. Hasegawa H, Hiki K, Sawamura T, et al. Purification of a novel endothelin-converting enzyme specific for big endothelin-3. FEBS Lett. 1998;428:304-308.
7. Schmidt M, Kroger B, Jacob E, et al. Molecular characterization of human and bovine endothelin converting enzyme (ECE-1). FEBS Lett. 1994;356:238-243.
8. Jeng AY, Mulder P, Kwan AL, Battistini B. Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications. Can J Physiol Pharmacol. 2002;80:440-449.
9. Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y, Kido H. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol 1997;159:1987-1992.
10. Kohan DE. Endothelin synthesis by rabbit renal tubule cells. Am J Physiol. 1991;261(2, pt 2):F221-F226.
11. Glassberg MK, Ergul A, Wanner A, Puett D. Endothelin-1 promotes mitogenesis in airway smooth muscle cells. Am J Respir Cell Mol Biol. 1994;10:316-321.
12. Sessa WC, Kaw S, Hecker M, Vane JR. The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochem Biophys Res Commun. 1991;174:613-618.
13. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994;46:325-415.
14. Kennedy RL, Haynes WG, Webb DJ. Endothelins as regulators of growth and function in endocrine tissues. Clin Endocrinol (Oxf). 1993;39:259-265.
15. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens. 1998;16:1081-1098.
16. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 1992;267:16066-16068.
17. Dohi Y, Hahn AW, Boulanger CM, Buhler FR, Luscher TF. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension. 1992;19:131-137.
18. Bakris GL, Fairbanks R, Traish AM. Arginine vasopressin stimulates human mesangial cell production of endothelin. J Clin Invest. 1991;87:1158-1164.
19. Fukunaga M, Yura T, Badr KF. Stimulatory effect of 8-Epi-PGF2 alpha, an F2-isoprostane, on endothelin-1 release. J Cardiovasc Pharmacol. 1995;26(suppl 3):S51-S52.
20. Auch-Schwelk W, Vanhoutte PM. Endothelium-derived contracting factor released by serotonin in the aorta of the spontaneously hypertensive rat. Am J Hypertens. 1991;4:769-772.
21. Boulanger CM, Tanner FC, Bea ML, Hahn AW, Werner A, Luscher TF. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res. 1992;70:1191-1197.
22. Schnermann JB, Zhu XL, Shu X, et al. Regulation of endothelin production and secretion in cultured collecting duct cells by endogenous transforming growth factor-beta. Endocrinology. 1996;137:5000-5008.
23. Ohde H, Morimoto S, Ogihara T. Bradykinin suppresses endothelin-induced contraction of coronary artery through its B2-receptor on the endothelium. Biochem Int. 1991;23:1127-1132.
24. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990;85:587-590.
25. Prins BA, Hu RM, Nazario B, et al. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem. 1994;269:11938-11944.
26. Wada A, Tsutamato T, Maeda Y, Kanamori T, Matsuda Y, Kinoshita M. Endogenous atrial natriuretic peptide inhibits endothelin-1 secretion in dogs with severe congestive heart failure. Am J Physiol. 1996;270(5, pt 2):H1819-H1824.
27. Kohno M, Kano H, Horio T, Yokokawa K, Yasunari K, Takeda T. Inhibition of endothelin production by adrenomedullin in vascular smooth muscle cells. Hypertension. 1995;25:1185-1190.
28. Ortiz MC, Manriquez MC, Romero JC, Juncos LA. Antioxidants block angiotensin II-induced increases in blood pressure and endothelin. Hypertension. 2001;38(3, pt 2):655-659.
29. Ortiz MC, Sanabria E, Manriquez MC, Romero JC, Juncos LA. Role of endothelin and isoprostanes in slow pressor responses to angiotensin II. Hypertension. 2001;37(2, pt 2):505-510.
30. Yoshizumi M, Kurihara H, Sugiyama T, et al. Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem Biophys Res Commun. 1989;161:859-864.
31. Malek AM, Greene AL, Izumo S. Regulation of endothelin 1 gene by fluid shear stress is transcriptionally mediated and independent of protein kinase C and cAMP. Proc Natl Acad Sci U S A. 1993;90:5999-6003.
32. Romero JC, Knox FG. Mechanisms underlying pressure-related natriuresis: the role of the renin-angiotensin and prostaglandin systems: state of the art lecture. Hypertension. 1988;11(6, pt 2):724-738.
33. Masaki T. Tissue specificity of the endothelin-induced responses. J Cardiovasc Pharmacol. 1991;17(suppl 7):S1-S4.
34. Hoyer D, Waeber C, Palacios JM. [125I]endothelin-1 binding sites: autoradiographic studies in the brain and periphery of various species including humans. J Cardiovasc Pharmacol. 1989;13(suppl 5):S162-S165.
35. Williams DL Jr, Jones KL, Colton CD, Nutt RF. Identification of high affinity endothelin-1 receptor subtypes in human tissues. Biochem Biophys Res Commun. 1991;180:475-480.
36. Lin HY, Kaji EH, Winkel GK, Ives HE, Lodish HF. Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor. Proc Natl Acad Sci U S A. 1991;88:3185-3189.
37. Conant AR, Oo AY, Dashwood MR, et al. Endothelin receptors in cultured and native human radial artery smooth muscle. J Cardiovasc Pharmacol. 2002;39:130-141.
38. Dockrell ME, Webb DJ, Williams BC. Activation of the endothelin B receptor causes a dose-dependent accumulation of cyclic GMP in human platelets. Blood Coagul Fibrinolysis. 1996;7:178-180.
39. Davenport AP, Morton AJ, Brown MJ. Localization of endothelin-1 (ET-1), ET-2, and ET-3, mouse VIC, and sarafotoxin S6b binding sites in mammalian heart and kidney. J Cardiovasc Pharmacol. 1991;17(suppl 7):S152-S155.
40. Lee ME, Dhadly MS, Temizer DH, Clifford JA, Yoshizumi M, Quertermous T. Regulation of endothelin-1 gene expression by Fos and Jun. J Biol Chem. 1991;266:19034-19039.
41. Abassi ZA, Tate JE, Golomb E, Keiser HR. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension. 1992;20:89-95.
42. Fagny C, Michel A, Nortier J, Deschodt-Lanckman M. Enzymatic degradation of endothelin-1 by activated human polymorpnonuclear neutrophils. Regul Pept. 1992;42:27-37.
43. Hirata Y, Emori T, Eguchi S, et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest. 1993;91:1367-1373.
44. Jougasaki M, Schirger JA, Simari RD, Burnett JC Jr. Autocrine role for the endothelin-B receptor in the secretion of adrenomedullin. Hypertension. 1998;32:917-922.
45. Yang ZH, Richard V, von Segesser L, et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries: a new mechanism of vasospasm? Circulation. 1990;82:188-195.
46. Haynes WG, Ferro CJ, O'Kane KP, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 1996;93:1860-1870.
47. Niranjan V, Telemaque S, deWit D, Gerard RD, Yanagisawa M. Systemic hypertension induced by hepatic overexpression of human preproendothelin-1 in rats. J Clin Invest. 1996;98:2364-2372.
48. Lerman A, Hildebrand FL Jr, Margulies KB, et al. Endothelin: a new cardiovascular regulatory peptide. Mayo Clin Proc. 1990;65:1441-1455.
49. Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature. 1994;368:703-710.
50. Ohuchi T, Kuwaki T, Ling GY, et al. Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am J Physiol. 1999;276(4, pt 2):R1071-1077.
51. Lerman A, Holmes DR Jr, Bell MR, Garratt KN, Nishimura RA, Burnett JC Jr. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation. 1995;92:2426-2431.
52. Russell FD, Skepper JN, Davenport AP. Detection of endothelin receptors in human coronary artery vascular smooth muscle cells but not endothelial cells by using electron microscope autoradiography. J Cardiovasc Pharmacol. 1997;29:820-826.
53. Best PJ, Lerman LO, Romero JC, Richardson D, Holmes DR Jr, Lerman A. Coronary endothelial function is preserved with chronic endothelin receptor antagonism in experimental hypercholesterolemia in vitro. Arterioscler Thromb Vasc Biol. 1999;19:2769-2775.
54. Mathew V, Hasdai D, Lerman A. The role of endothelin in coronary atherosclerosis. Mayo Clin Proc. 1996;71:769-777.
55. Kramer BK, Smith TW, Kelly RA. Endothelin and increased contractility in adult rat ventricular myocytes: role of intracellular alkalosis induced by activation of the protein kinase C-dependent Na(+)-H+ exchanger. Circ Res. 1991;68:269-279.
56. Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy. Hypertension. 1994;24:183-188.
57. Schiffrin EL, Lariviere R, Li JS, Sventek P, Touyz RM. Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension. 1995;25(4, pt 2):769-773.
58. Piuhola J, Szokodi I, Kinnunen P, et al. Endothelin-1 contributes to the Frank-Starling response in hypertrophic rat hearts. Hypertension. 2003;41:93-98.
59. Yorikane R, Shiga H, Miyake S, Koike H. Evidence for direct arrhythmogenic action of endothelin. Biochem Biophys Res Commun. 1990;173:457-462.
60. Geller L, Merkely B, Szokodi I, et al. Electrophysiological effects of intrapericardial infusion of endothelin-1. Pacing Clin Electrophysiol. 1998;21(1, pt 2):151-156.
61. Markewitz BA, Kohan DE. Role of intrarenal endothelin in the generation and maintenance of hypertension. Miner Electrolyte Metab. 1995;21:342-352.
62. Wilkes BM, Ruston AS, Mento P, et al. Characterization of endothelin 1 receptor and signal transduction mechanisms in rat medullary interstitial cells. Am J Physiol. 1991;260(4, pt 2):F579-F589.
63. Nambi P. Endothelin receptors in normal and diseased kidneys. Clin Exp Pharmacol Physiol. 1996;23:326-330.
64. Orth SR, Amann K, Gehlen F, et al. Adult human mesangial cells (HMCs) express endothelin-B-receptors which mediate endothelin-1-induced cell growth. J Cardiovasc Pharmacol. 2000;36(5, suppl 1):S232-S237.
65. Stacy DL, Scott JW, Granger JP. Control of renal function during intrarenal infusion of endothelin. Am J Physiol. 1990;258(5, pt 2):F1232-F1236.
66. Matsuura T, Miura K, Ebara T, et al. Renal vascular effects of the selective endothelin receptor antagonists in anaesthetized rats. Br J Pharmacol. 1997;122:81-86.
67. Qiu C, Baylis C. Endothelin and angiotensin mediate most glomerular responses to nitric oxide inhibition. Kidney Int. 1999;55:2390-2396.
68. Hoffman A, Abassi ZA, Brodsky S, Ramadan R, Winaver J. Mechanisms of big endothelin-1-induced diuresis and natriuresis: role of ET(B) receptors. Hypertension. 2000;35:732-739.
69. Garcia NH, Garvin JL. Endothelin's biphasic effect on fluid absorption in the proximal straight tubule and its inhibitory cascade. J Clin Invest. 1994;93:2572-2577.
70. Plato CF, Stoos BA, Wang D, Garvin JL. Endogenous nitric oxide inhibits chloride transport in the thick ascending limb. Am J Physiol. 1999;276(1, pt 2):F159-F163.
71. Edwards RM, Stack EJ, Pullen M, Nambi P. Endothelin inhibits vasopressin action in rat inner medullary collecting duct via the ETB receptor. J Pharmacol Exp Ther. 1993;267:1028-1033.
72. Wong NL, Sonntag M, Tsui JK. Attenuation of renal vasopressin V2 receptor upregulation by bosentan, an ETA/ETB receptor antagonist. Metabolism. 2003;52:1141-1146.
73. Brodsky S, Abassi Z, Wessale J, Ramadan R, Winaver J, Hoffman A. Effects of A-192621.1, a specific endothelin-B antagonist, on intrarenal hemodynamic responses to endothelin-1. J Cardiovasc Pharmacol. 2000;36(5, suppl 1):S311-S313.
74. Abassi Z, Gurbanov K, Rubinstein I, Better OS, Hoffman A, Winaver J. Regulation of intrarenal blood flow in experimental heart failure: role of endothelin and nitric oxide. Am J Physiol. 1998;274(4, pt 2):F766-F774.
75. Vierhapper H, Wagner O, Nowotny P, Waldhausl W. Effect of endothelin-1 in man. Circulation. 1990;81:1415-1418.
76. Kassab S, Novak J, Miller T, Kirchner K, Granger J. Role of endothelin in mediating the attenuated renal hemodynamics in Dahl salt-sensitive hypertension. Hypertension. 1997;30(3, pt 2):682-686.
77. Pollock DM, Pollock JS. Evidence for endothelin involvement in the response to high salt. Am J Physiol Renal Physiol. 2001;281:F144-F150.
78. Gariepy CE, Ohuchi T, Williams SC, Richardson JA, Yanagisawa M. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest. 2000;105:925-933.
79. Ballew JR, Watts SW, Fink GD. Effects of salt intake and angiotensin II on vascular reactivity to endothelin-1. J Pharmacol Exp Ther. 2001;296:345-350.
80. Hinojosa-Laborde C, Osborn JW Jr, Cowley AW Jr. Hemodynamic effects of endothelin in conscious rats. Am J Physiol. 1989;256(6, pt 2):H1742-H1746.
81. Sventek P, Turgeon A, Garcia R, Schiffrin EL. Vascular and cardiac overexpression of endothelin-1 gene in one-kidney, one clip Goldblatt hypertensive rats but only in the late phase of two-kidney one clip Goldblatt hypertension. J Hypertens. 1996;14:57-64.
82. Suzuki N, Miyauchi T, Tomobe Y, et al. Plasma concentrations of endothelin-1 in spontaneously hypertensive rats and DOCA-salt hypertensive rats. Biochem Biophys Res Commun. 1990;167:941-947.
83. Ikeda T, Ohta H, Okada M, et al. Pathophysiological roles of endothelin-1 in Dahl salt-sensitive hypertension. Hypertension. 1999;34:514-519.
84. Lariviere R, Thibault G, Schiffrin EL. Increased endothelin-lcontentin blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension. 1993;21:294-300.
85. Matsumura Y, Kuro T, Kobayashi Y, et al. Exaggerated vascular and renal pathology in endothelin-B receptor-deficient rats with deoxycorticosterone acetate-salt hypertension. Circulation. 2000;102:2765-2773.
86. Abdel-Sayed S, Nussberger J, Aubert JF, Gohlke P, Brunner HR, Brakch N. Measurement of plasma endothelin-1 in experimental hypertension and in healthy subjects. Am J Hypertens. 2003;16:515-521.
87. Intengan HD, Park JB, Schiffrin EL. Blood pressure and small arteries in DOCA-salt-treated genetically AVP-deficient rats: role of endothelin. Hypertension. 1999;34(4, pt 2):907-913.
88. Li L, Galligan JJ, Fink GD, Chen AF. Vasopressin induces vascular superoxide via endothelin-1 in mineralocorticoid hypertension. Hypertension. 2003;41(3, pt 2):663-668.
89. Sharifi AM, He G, Touyz RM, Schiffrin EL. Vascular endothelin-1 expression and effect of an endothelin ETA antagonist on structure and function of small arteries from stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1998;31(suppl 1):S309-S312.
90. Rothermund L, Luckert S, Kossmehl P, Paul M, Kreutz R. Renal endothelin ET(A)/ET(B) receptor imbalance differentiates salt-sensitive from salt-resistant spontaneous hypertension. Hypertension. 2001;37:275-280.
91. Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2003;284:R893-R912.
92. Ruef J, Moser M, Kubler W, Bode C. Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells. Cardiovasc Pathol. 2001;10:311-315.
93. Elijovich F, Laffer CL, Amador E, Gavras H, Bresnahan MR, Schiffrin EL. Regulation of plasma endothelin by salt in salt-sensitive hypertension. Circulation. 2001;103:263-268.
94. Takahashi K, Nammour TM, Fukunaga M, et al. Glomerular actions of a free radical-generated novel prostaglandin, 8- epi-prostaglandin F2 alpha, in the rat: evidence for interaction with thromboxane A2 receptors. J Clin Invest. 1992;90:136-141.
95. Deng LY, Schiffrin EL. Endothelin-1 gene expression in blood vessels and kidney of spontaneously hypertensive rats (SHR), L-NAME-treated SHR, and renovascular hypertensive rats. J Cardiovasc Pharmacol. 1998;31(suppl 1):S380-S383.
96. Diekmann F, Zart R, Thone-Reineke C, Bauer C, Neumayer HH, Hocher B. Regulation of the renal endothelin system in the two-kidney, one clip renal hypertensive rat. J Cardiovasc Pharmacol. 2000;36(5, suppl 1):S191-S194.
97. Meng S, Roberts LJ II, Cason GW, Curry TS, Manning RD Jr. Superoxide dismutase and oxidative stress in Dahl salt-sensitive and -resistant rats. Am J Physiol Regul Integr Comp Physiol. 2002;283:R732-R738.
98. Modesti PA, Cecioni I, Migliorini A, et al. Increased renal endothelin formation is associated with sodium retention and increased free water clearance. Am J Physiol. 1998;275(3, pt 2):H1070-H1077.
99. Morgan T, Aubert JF, Brunner H. Interaction between sodium intake, angiotensin II, and blood pressure as a cause of cardiac hypertrophy. Am J Hypertens. 2001;14(9, pt 1):914-920.
100. Ferri C, Bellini C, Desideri G, Mazzocchi C, De Siati L, Santucci A. Elevated plasma and urinary endothelin-I levels in human salt-sensitive hypertension. Clin Sci (Lond). 1997;93:35-41.
101. Schneider MP, Hilgers KF, Klingbeil AU, John S, Veelken R, Schmieder RE. Plasma endothelin is increased in early essential hypertension. Am J Hypertens. 2000;13(6, pt 1):579-585.
102. Lariviere R, Lebel M. Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol. 2003;81:607-621.
103. Bragulat E, de la Sierra A, Antonio MT, Coca A. Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension. 2001;37(2, pt 2):444-448.
104. Yanagisawa H, Yanagisawa M, Kapur RP, et al. Dual genetic path- ways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development. 1998;125:825-836.
105. Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension [published correction appears in Hypertension. 1997;29:912], Hypertension. 1996; 28:652-655.
106. Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens. 1997;15:57-63.
107. Letizia C, De Toma G, Cerci S, et al. Plasma endothelin-1 levels in patients with aldosterone-producing adenoma and pheochromocytoma. Clin Exp Hypertens. 1996;18:921-931.
108. Ferri C, Bellini C, Desideri G, et al. Clustering of endothelial markers of vascular damage in human salt-sensitive hypertension: influence of dietary sodium load and depletion. Hypertension. 1998;32:862-868.
109. Nicolaidou P, Georgouli H, Matsinos Y, et al. Endothelin-1 in children with acute poststreptococcal glomerulpnephritis and hypertension. Pediatr Int. 2003;45:35-38.
110. Ong AC, Newby LJ, Dashwood MR. Expression and cellular localisation of renal endothelin-1 and endothelin receptor subtypes in autosomal-dominant polycystic kidney disease. Nephron Exp Nephrol. 2003;93:e80-e86.
111. Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M. Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol Sci. 1998;19:5-8.
112. Hoffman A, Grossman E, Goldstein DS, Gill JR Jr, Keiser HR. Urinary excretion rate of endothelin-1 in patients with essential hypertension and salt sensitivity. Kidney Int. 1994;45:556-560.